Download PDF
Semin Neurol 2012; 32(04): 432-453
DOI: 10.1055/s-0032-1331814
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Guidelines for Acquiring and Reporting Clinical Neurospectroscopy

Alexander Lin
1   Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts
,
Thao Tran
2   MRS Unit, Huntington Medical Research Institutes, Pasadena, California
,
Stefan Bluml
3   Department of Radiology, Children's Hospital Boston, Los Angeles California
,
Sai Merugumala
1   Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts
,
Hui-Jun Liao
1   Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts
,
Brian D. Ross
1   Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts
2   MRS Unit, Huntington Medical Research Institutes, Pasadena, California
› Author Affiliations
Further Information

Publication History

Publication Date:
29 January 2013 (online)

    Permissions and Reprints

Corrected by:

Guidelines for Acquiring and Reporting Clinical NeurospectroscopySemin Neurol 2012; 32(05): 557-558
DOI: 10.1055/s-0033-1336414

Abstract

Since the advent of CPT 76390 in 1998, magnetic resonance spectroscopy (MRS) of the brain, or neurospectroscopy, has moved from the realm of academic research into that of the clinical world. All major MR manufacturers have aided in the endeavor by automating neurospectroscopy so that it no longer requires an MR physicist and is a push-button technique that can be run by technologists just as a typical MR sequence. Thousands of studies have demonstrated the clinical efficacy of neurospectroscopy, and there are many medical reviews of how this technique can be applied across a wide range of neurologic disorders. However, few studies address the practical issue of acquiring and reporting neurospectroscopy in a clinical practice. Based on clinical experience at three different sites across the country and nearly two decades of applications training for technologists and radiologists at international clinical neurospectroscopy courses, the guidelines described in this article demonstrate proven protocols for clinical diagnosis and outline the strategies involved in acquiring, interpreting, and reporting clinical neurospectroscopy successfully. A standard operating procedure used across the three sites is described and high reproducibility across different platforms is shown.

Keywords

magnetic resonance spectroscopy - clinical efficacy - standardization - neurologic disease - reproducibility
 

  • References

  • 1 Lin AP, Tran TT, Ross BD. Impact of evidence-based medicine on magnetic resonance spectroscopy. NMR Biomed 2006; 19 (4) 476-483
    CrossrefPubMedGoogle Scholar
  • 2 Ross B, Bluml S. Magnetic resonance spectroscopy of the human brain. Anat Rec 2001; 265 (2) 54-84
    CrossrefPubMedGoogle Scholar
  • 3 Tran T, Ross B, Lin A. Magnetic resonance spectroscopy in neurological diagnosis. Neurol Clin 2009; 27 (1) 21-60, xiii xiii
    CrossrefPubMedGoogle Scholar
  • 4 Xu V, Chan H, Lin AP , et al. MR spectroscopy in diagnosis and neurological decision-making. Semin Neurol 2008; 28 (4) 407-422
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Zhu H, Barker PB. MR spectroscopy and spectroscopic imaging of the brain. Methods Mol Biol 2011; 711: 203-226
    PubMedGoogle Scholar
  • 6 Alger JR. Quantitative proton magnetic resonance spectroscopy and spectroscopic imaging of the brain: a didactic review. Top Magn Reson Imaging 2010; 21 (2) 115-128
    CrossrefPubMedGoogle Scholar
  • 7 Drost DJ, Riddle WR, Clarke GD. AAPM MR Task Group #9. Proton magnetic resonance spectroscopy in the brain: report of AAPM MR Task Group #9. Med Phys 2002; 29 (9) 2177-2197
    CrossrefPubMedGoogle Scholar
  • 8 Law M. MR spectroscopy of brain tumors. Top Magn Reson Imaging 2004; 15 (5) 291-313
    CrossrefPubMedGoogle Scholar
  • 9 Castillo M, Kwock L, Scatliff J, Mukherji SK. Proton MR spectroscopy in neoplastic and non-neoplastic brain disorders. Magn Reson Imaging Clin N Am 1998; 6 (1) 1-20
    PubMedGoogle Scholar
  • 10 Gillies RJ, Morse DL. In vivo magnetic resonance spectroscopy in cancer. Annu Rev Biomed Eng 2005; 7: 287-326
    CrossrefPubMedGoogle Scholar
  • 11 McIntyre DJ, Madhu B, Lee SH, Griffiths JR. Magnetic resonance spectroscopy of cancer metabolism and response to therapy. Radiat Res 2012; 177 (4) 398-435
    CrossrefPubMedGoogle Scholar
  • 12 Sibtain NA, Howe FA, Saunders DE. The clinical value of proton magnetic resonance spectroscopy in adult brain tumours. Clin Radiol 2007; 62 (2) 109-119
    CrossrefPubMedGoogle Scholar
  • 13 Negendank W. Studies of human tumors by MRS: a review. NMR Biomed 1992; 5 (5) 303-324
    CrossrefPubMedGoogle Scholar
  • 14 Howe FA, Opstad KS. 1H MR spectroscopy of brain tumours and masses. NMR Biomed 2003; 16 (3) 123-131
    CrossrefPubMedGoogle Scholar
  • 15 Hollingworth W, Medina LS, Lenkinski RE , et al. A systematic literature review of magnetic resonance spectroscopy for the characterization of brain tumors. AJNR Am J Neuroradiol 2006; 27 (7) 1404-1411
    PubMedGoogle Scholar
  • 16 Cecil KM, Lenkinski RE. Proton MR spectroscopy in inflammatory and infectious brain disorders. Neuroimaging Clin N Am 1998; 8 (4) 863-880
    PubMedGoogle Scholar
  • 17 Chang L, Ernst T. MR spectroscopy and diffusion-weighted MR imaging in focal brain lesions in AIDS. Neuroimaging Clin N Am 1997; 7 (3) 409-426
    PubMedGoogle Scholar
  • 18 Kapsalaki EZ, Gotsis ED, Fountas KN. The role of proton magnetic resonance spectroscopy in the diagnosis and categorization of cerebral abscesses. Neurosurg Focus 2008; 24 (6) E7
    PubMedGoogle Scholar
  • 19 Kuzniecky R. Clinical applications of MR spectroscopy in epilepsy. Neuroimaging Clin N Am 2004; 14 (3) 507-516
    CrossrefPubMedGoogle Scholar
  • 20 Ranjeva JP, Confort-Gouny S, Le Fur Y, Cozzone PJ. Magnetic resonance spectroscopy of brain in epilepsy. Childs Nerv Syst 2000; 16 (4) 235-241
    CrossrefPubMedGoogle Scholar
  • 21 Ross BD, Bluml S, Cowan R, Danielsen E, Farrow N, Tan J. In vivo MR spectroscopy of human dementia. Neuroimaging Clin N Am 1998; 8 (4) 809-822
    PubMedGoogle Scholar
  • 22 Kantarci K. 1H magnetic resonance spectroscopy in dementia. Br J Radiol 2007; 80 (Spec No 2) S146-S152
    CrossrefPubMedGoogle Scholar
  • 23 Firbank MJ, Harrison RM, O'Brien JT. A comprehensive review of proton magnetic resonance spectroscopy studies in dementia and Parkinson's disease. Dement Geriatr Cogn Disord 2002; 14 (2) 64-76
    CrossrefPubMedGoogle Scholar
  • 24 Grover VP, Dresner MA, Forton DM , et al. Current and future applications of magnetic resonance imaging and spectroscopy of the brain in hepatic encephalopathy. World J Gastroenterol 2006; 12 (19) 2969-2978
    PubMedGoogle Scholar
  • 25 Ross BD, Danielsen ER, Blüml S. Proton magnetic resonance spectroscopy: the new gold standard for diagnosis of clinical and subclinical hepatic encephalopathy?. Dig Dis 1996; 14 (Suppl. 01) 30-39
    CrossrefPubMedGoogle Scholar
  • 26 Cecil KM. MR spectroscopy of metabolic disorders. Neuroimaging Clin N Am 2006; 16 (1) 87-116, viii viii
    CrossrefPubMedGoogle Scholar
  • 27 Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AM. N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol 2007; 81 (2) 89-131
    CrossrefPubMedGoogle Scholar
  • 28 Saneto RP, Friedman SD, Shaw DW. Neuroimaging of mitochondrial disease. Mitochondrion 2008; 8 (5–6) 396-413
    CrossrefPubMedGoogle Scholar
  • 29 Schiffmann R, van der Knaap MS. The latest on leukodystrophies. Curr Opin Neurol 2004; 17 (2) 187-192
    CrossrefPubMedGoogle Scholar
  • 30 Cady EB. Magnetic resonance spectroscopy in neonatal hypoxic-ischaemic insults. Childs Nerv Syst 2001; 17 (3) 145-149
    CrossrefPubMedGoogle Scholar
  • 31 Saunders DE. MR spectroscopy in stroke. Br Med Bull 2000; 56 (2) 334-345
    CrossrefPubMedGoogle Scholar
  • 32 Ricci Jr PE. Proton MR spectroscopy in ischemic stroke and other vascular disorders. Neuroimaging Clin N Am 1998; 8 (4) 881-900
    PubMedGoogle Scholar
  • 33 De Stefano N, Filippi M. MR spectroscopy in multiple sclerosis. J Neuroimaging 2007; 17 (Suppl. 01) 31S-35S
    CrossrefPubMedGoogle Scholar
  • 34 Narayana PA. Magnetic resonance spectroscopy in the monitoring of multiple sclerosis. J Neuroimaging 2005; 15 (4, Suppl) 46S-57S
    CrossrefPubMedGoogle Scholar
  • 35 Arnold DL, De Stefano N, Narayanan S, Matthews PM. Proton MR spectroscopy in multiple sclerosis. Neuroimaging Clin N Am 2000; 10 (4) 789-798 , ix–x
    PubMedGoogle Scholar
  • 36 Lin AP, Liao HJ, Merugumala SK, Prabhu SP, Meehan III WP, Ross BD. Metabolic imaging of mild traumatic brain injury. Brain Imaging Behav 2012; 6 (2) 208-223
    CrossrefPubMedGoogle Scholar
  • 37 Marino S, Ciurleo R, Bramanti P, Federico A, De Stefano N. 1H-MR spectroscopy in traumatic brain injury. Neurocrit Care 2011; 14 (1) 127-133
    CrossrefPubMedGoogle Scholar
  • 38 Garnett MR, Cadoux-Hudson TA, Styles P. How useful is magnetic resonance imaging in predicting severity and outcome in traumatic brain injury?. Curr Opin Neurol 2001; 14 (6) 753-757
    CrossrefPubMedGoogle Scholar
  • 39 Brooks WM, Friedman SD, Gasparovic C. Magnetic resonance spectroscopy in traumatic brain injury. J Head Trauma Rehabil 2001; 16 (2) 149-164
    CrossrefPubMedGoogle Scholar
  • 40 Panigrahy A, Blüml S. Advances in magnetic resonance imaging of the injured neonatal brain. Pediatr Ann 2008; 37 (6) 395-402
    CrossrefPubMedGoogle Scholar
  • 41 Panigrahy A, Borzage M, Blüml S. Basic principles and concepts underlying recent advances in magnetic resonance imaging of the developing brain. Semin Perinatol 2010; 34 (1) 3-19
    CrossrefPubMedGoogle Scholar
  • 42 Hoon Jr AH, Melhem ER. Neuroimaging: applications in disorders of early brain development. J Dev Behav Pediatr 2000; 21 (4) 291-302
    CrossrefPubMedGoogle Scholar
  • 43 Kułak W, Sobaniec W. Molecular mechanisms of brain plasticity: neurophysiologic and neuroimaging studies in the developing patients. Rocz Akad Med Bialymst 2004; 49: 227-236
    PubMedGoogle Scholar
  • 44 Martin WRW. MR spectroscopy in neurodegenerative disease. Mol Imaging Biol 2007; 9 (4) 196-203
    CrossrefPubMedGoogle Scholar
  • 45 Pioro EP. Proton magnetic resonance spectroscopy (1H-MRS) in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1 (Suppl. 02) S7-S16
    CrossrefPubMedGoogle Scholar
  • 46 Harris RE, Clauw DJ. Imaging central neurochemical alterations in chronic pain with proton magnetic resonance spectroscopy. Neurosci Lett 2012; 520 (2) 192-196
    CrossrefPubMedGoogle Scholar
  • 47 Mountford CE, Stanwell P, Lin A, Ramadan S, Ross B. Neurospectroscopy: the past, present and future. Chem Rev 2010; 110 (5) 3060-3086
    CrossrefPubMedGoogle Scholar
  • 48 Broniscer A, Gajjar A, Bhargava R , et al. Brain stem involvement in children with neurofibromatosis type 1: role of magnetic resonance imaging and spectroscopy in the distinction from diffuse pontine glioma. Neurosurgery 1997; 40 (2) 331-337 , discussion 337–338
    CrossrefPubMedGoogle Scholar
  • 49 Castillo M, Kwock L, Courvoisie HE, Hooper SR, Greenwood RS. Proton MR spectroscopy in psychiatric and neurodevelopmental childhood disorders: early experience. Neuroimaging Clin N Am 1998; 8 (4) 901-912
    PubMedGoogle Scholar
  • 50 Lin DD, Barker PB. Neuroimaging of phakomatoses. Semin Pediatr Neurol 2006; 13 (1) 48-62
    CrossrefPubMedGoogle Scholar
  • 51 Arora A, Neema M, Stankiewicz J , et al. Neuroimaging of toxic and metabolic disorders. Semin Neurol 2008; 28 (4) 495-510
    Article in Thieme ConnectPubMedGoogle Scholar
  • 52 Licata SC, Renshaw PF. Neurochemistry of drug action: insights from proton magnetic resonance spectroscopic imaging and their relevance to addiction. Ann N Y Acad Sci 2010; 1187: 148-171
    CrossrefPubMedGoogle Scholar
  • 53 Meyerhoff DJ, Durazzo TC. Proton magnetic resonance spectroscopy in alcohol use disorders: a potential new endophenotype?. Alcohol Clin Exp Res 2008; 32 (7) 1146-1158
    CrossrefPubMedGoogle Scholar
  • 54 Panigrahy A, Blüml S. Advances in magnetic resonance neuroimaging techniques in the evaluation of neonatal encephalopathy. Top Magn Reson Imaging 2007; 18 (1) 3-29
    CrossrefPubMedGoogle Scholar
  • 55 Hunter JV, Wang ZJ. MR spectroscopy in pediatric neuroradiology. Magn Reson Imaging Clin N Am 2001; 9 (1) 165-189, ix ix
    PubMedGoogle Scholar
  • 56 Nucci-da-Silva MP, Amaro Jr E. A systematic review of magnetic resonance imaging and spectroscopy in brain injury after drowning. Brain Inj 2009; 23 (9) 707-714
    CrossrefPubMedGoogle Scholar
  • 57 Gómez-Ansón B, MacManus DG, Parker GJ , et al. In vivo 1H-magnetic resonance spectroscopy of the spinal cord in humans. Neuroradiology 2000; 42 (7) 515-517
    CrossrefPubMedGoogle Scholar
  • 58 Lammertse D, Dungan D, Dreisbach J , et al; National Institute on Disability and Rehabilitation. Neuroimaging in traumatic spinal cord injury: an evidence-based review for clinical practice and research. J Spinal Cord Med 2007; 30 (3) 205-214
    PubMedGoogle Scholar
  • 59 Caverzasi E, Pichiecchio A, Calligaro A , et al. Complications in major depressive disorder therapy: a review of magnetic resonance spectroscopy studies. Funct Neurol 2008; 23 (3) 129-132
    PubMedGoogle Scholar
  • 60 Karl A, Werner A. The use of proton magnetic resonance spectroscopy in PTSD research—meta-analyses of findings and methodological review. Neurosci Biobehav Rev 2010; 34 (1) 7-22
    CrossrefPubMedGoogle Scholar
  • 61 Keshavan MS, Stanley JA, Pettegrew JW. Magnetic resonance spectroscopy in schizophrenia: methodological issues and findings—part II. Biol Psychiatry 2000; 48 (5) 369-380
    Google Scholar
  • 62 Stanley JA, Pettegrew JW, Keshavan MS. Magnetic resonance spectroscopy in schizophrenia: methodological issues and findings—part I. Biol Psychiatry 2000; 48 (5) 357-368
    CrossrefPubMedGoogle Scholar
  • 63 Sundgren PC. MR spectroscopy in radiation injury. AJNR Am J Neuroradiol 2009; 30 (8) 1469-1476
    CrossrefPubMedGoogle Scholar
  • 64 Nelson SJ. Imaging of brain tumors after therapy. Neuroimaging Clin N Am 1999; 9 (4) 801-819
    PubMedGoogle Scholar
  • 65 Payne GS, Leach MO. Applications of magnetic resonance spectroscopy in radiotherapy treatment planning. Br J Radiol 2006; 79 (Spec No 1) S16-S26
    CrossrefPubMedGoogle Scholar
  • 66 Lai PH, Hsu SS, Lo YK, Ding SW. Role of diffusion-weighted imaging and proton MR spectroscopy in distinguishing between pyogenic brain abscess and necrotic brain tumor. Acta Neurol Taiwan 2004; 13 (3) 107-113
    PubMedGoogle Scholar
  • 67 Peterson PL, Axford JS, Isenberg D. Imaging in CNS lupus. Best Pract Res Clin Rheumatol 2005; 19 (5) 727-739
    CrossrefPubMedGoogle Scholar
  • 68 Tanabe J, Weiner MW. MRI-MRS of the brain in systemic lupus erythematosus. How do we use it to understand causes of clinical signs?. Ann N Y Acad Sci 1997; 823: 169-184
    CrossrefPubMedGoogle Scholar
  • 69 Caverzasi E, Pichiecchio A, Poloni GU , et al. Magnetic resonance spectroscopy in the evaluation of treatment efficacy in unipolar major depressive disorder: a review of the literature. Funct Neurol 2012; 27 (1) 13-22
    PubMedGoogle Scholar
  • 70 Gonzalez-Toledo E, Kelley RE, Minagar A. Role of magnetic resonance spectroscopy in diagnosis and management of multiple sclerosis. Neurol Res 2006; 28 (3) 280-283
    CrossrefPubMedGoogle Scholar
  • 71 Lin A, Ross BD, Harris K, Wong W. Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making. NeuroRx 2005; 2 (2) 197-214
    CrossrefPubMedGoogle Scholar
  • 72 Moats RA, Watson L, Shonk T , et al. Added value of automated clinical proton MR spectroscopy of the brain. J Comput Assist Tomogr 1995; 19 (3) 480-491
    CrossrefPubMedGoogle Scholar
  • 73 Webb PG, Sailasuta N, Kohler SJ, Raidy T, Moats RA, Hurd RE. Automated single-voxel proton MRS: technical development and multisite verification. Magn Reson Med 1994; 31 (4) 365-373
    CrossrefPubMedGoogle Scholar
  • 74 ACR–ASNR Practice Guideline for the Performance and Interpretation of Magnetic . Resonance Spectroscopy of the Central Nervous System. 2008. Available at: http://www.acr.org/∼/media/B0AF516E53234DA399EF305525504249.pdf . Accessed October 10, 2012
    PubMedGoogle Scholar
  • 75 Rosen Y, Lenkinski RE. Recent advances in magnetic resonance neurospectroscopy. Neurotherapeutics 2007; 4 (3) 330-345
    CrossrefPubMedGoogle Scholar
  • 76 Ashwal S, Holshouser BA, Shu SK , et al. Predictive value of proton magnetic resonance spectroscopy in pediatric closed head injury. Pediatr Neurol 2000; 23 (2) 114-125
    CrossrefPubMedGoogle Scholar
  • 77 Camicioli RM, Korzan JR, Foster SL , et al. Posterior cingulate metabolic changes occur in Parkinson's disease patients without dementia. Neurosci Lett 2004; 354 (3) 177-180
    CrossrefPubMedGoogle Scholar
  • 78 Gropman A. Brain imaging in urea cycle disorders. Mol Genet Metab 2010; 100 (Suppl. 01) S20-S30
    CrossrefPubMedGoogle Scholar
  • 79 Shimizu E, Hashimoto K, Ochi S , et al. Posterior cingulate gyrus metabolic changes in chronic schizophrenia with generalized cognitive deficits. J Psychiatr Res 2007; 41 (1–2) 49-56
    CrossrefPubMedGoogle Scholar
  • 80 Hsu YY, Chen MC, Lim KE, Chang C. Reproducibility of hippocampal single-voxel proton MR spectroscopy and chemical shift imaging. AJR Am J Roentgenol 2001; 176 (2) 529-536
    CrossrefPubMedGoogle Scholar
  • 81 Kreis R. Issues of spectral quality in clinical 1H-magnetic resonance spectroscopy and a gallery of artifacts. NMR Biomed 2004; 17 (6) 361-381
    CrossrefPubMedGoogle Scholar
  • 82 Kallenberg K, Bock HC, Helms G , et al. Untreated glioblastoma multiforme: increased myo-inositol and glutamine levels in the contralateral cerebral hemisphere at proton MR spectroscopy. Radiology 2009; 253 (3) 805-812
    CrossrefPubMedGoogle Scholar
  • 83 Sundgren PC, Nagesh V, Elias A , et al. Metabolic alterations: a biomarker for radiation-induced normal brain injury-an MR spectroscopy study. J Magn Reson Imaging 2009; 29 (2) 291-297
    CrossrefPubMedGoogle Scholar
  • 84 Estève F, Rubin C, Grand S, Kolodié H, Le Bas JF. Transient metabolic changes observed with proton MR spectroscopy in normal human brain after radiation therapy. Int J Radiat Oncol Biol Phys 1998; 40 (2) 279-286
    CrossrefPubMedGoogle Scholar
  • 85 Sijens PE, Oudkerk M, van Dijk P, Levendag PC, Vecht CJ. 1H MR spectroscopy monitoring of changes in choline peak area and line shape after Gd-contrast administration. Magn Reson Imaging 1998; 16 (10) 1273-1280
    CrossrefPubMedGoogle Scholar
  • 86 Sijens PE, van den Bent MJ, Nowak PJ, van Dijk P, Oudkerk M. 1H chemical shift imaging reveals loss of brain tumor choline signal after administration of Gd-contrast. Magn Reson Med 1997; 37 (2) 222-225
    CrossrefPubMedGoogle Scholar
  • 87 Smith JK, Kwock L, Castillo M. Effects of contrast material on single-volume proton MR spectroscopy. AJNR Am J Neuroradiol 2000; 21 (6) 1084-1089
    PubMedGoogle Scholar
  • 88 Lima EC, Otaduy MC, Tsunemi M , et al. The effect of paramagnetic contrast in choline peak in patients with glioblastoma multiforme might not be significant. AJNR Am J Neuroradiol 2012;
    PubMedGoogle Scholar
  • 89 Murphy PS, Dzik-Jurasz AS, Leach MO, Rowland IJ. The effect of Gd-DTPA on T(1)-weighted choline signal in human brain tumours. Magn Reson Imaging 2002; 20 (1) 127-130
    CrossrefPubMedGoogle Scholar
  • 90 Lin AP, Ross BD. Short-echo time proton MR spectroscopy in the presence of gadolinium. J Comput Assist Tomogr 2001; 25 (5) 705-712
    CrossrefPubMedGoogle Scholar
  • 91 Murphy PS, Leach MO, Rowland IJ. The effects of paramagnetic contrast agents on metabolite protons in aqueous solution. Phys Med Biol 2002; 47 (6) N53-N59
    PubMedGoogle Scholar
  • 92 Candiota AP, Majós C, Julià-Sapé M , et al. Non-invasive grading of astrocytic tumours from the relative contents of myo-inositol and glycine measured by in vivo MRS. JBR-BTR 2011; 94 (6) 319-329
    PubMedGoogle Scholar
  • 93 Kim JH, Chang KH, Na DG , et al. 3T 1H-MR spectroscopy in grading of cerebral gliomas: comparison of short and intermediate echo time sequences. AJNR Am J Neuroradiol 2006; 27 (7) 1412-1418
    PubMedGoogle Scholar
  • 94 Galanaud D, Chinot O, Nicoli F , et al. Use of proton magnetic resonance spectroscopy of the brain to differentiate gliomatosis cerebri from low-grade glioma. J Neurosurg 2003; 98 (2) 269-276
    CrossrefPubMedGoogle Scholar
  • 95 Panigrahy A, Krieger MD, Gonzalez-Gomez I , et al. Quantitative short echo time 1H-MR spectroscopy of untreated pediatric brain tumors: preoperative diagnosis and characterization. AJNR Am J Neuroradiol 2006; 27 (3) 560-572
    PubMedGoogle Scholar
  • 96 Inglese M, Spindler M, Babb JS, Sunenshine P, Law M, Gonen O. Field, coil, and echo-time influence on sensitivity and reproducibility of brain proton MR spectroscopy. AJNR Am J Neuroradiol 2006; 27 (3) 684-688
    PubMedGoogle Scholar
  • 97 Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993; 30 (6) 672-679
    CrossrefPubMedGoogle Scholar
  • 98 Naressi A, Couturier C, Castang I, de Beer R, Graveron-Demilly D. Java-based graphical user interface for MRUI, a software package for quantitation of in vivo/medical magnetic resonance spectroscopy signals. Comput Biol Med 2001; 31 (4) 269-286
    CrossrefPubMedGoogle Scholar
  • 99 Delikatny EJ, Chawla S, Leung DJ, Poptani H. MR-visible lipids and the tumor microenvironment. NMR Biomed 2011; 24 (6) 592-611
    PubMedGoogle Scholar
  • 100 Haseler LJ, Arcinue E, Danielsen ER, Bluml S, Ross BD. Evidence from proton magnetic resonance spectroscopy for a metabolic cascade of neuronal damage in shaken baby syndrome. Pediatrics 1997; 99 (1) 4-14
    CrossrefPubMedGoogle Scholar
  • 101 Howe FA, Barton SJ, Cudlip SA , et al. Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy. Magn Reson Med 2003; 49 (2) 223-232
    CrossrefPubMedGoogle Scholar
  • 102 Harris K, Lin A, Bhattacharya P, Tran T, Wong W, Ross B. Regulation of NAA-synthesis in the human brain in vivo: Canavan's disease, Alzheimer's disease and schizophrenia. Adv Exp Med Biol 2006; 576: 263-273 , discussion 361–363
    PubMedGoogle Scholar
  • 103 Ross BD. Biochemical considerations in 1H spectroscopy. Glutamate and glutamine; myo-inositol and related metabolites. NMR Biomed 1991; 4 (2) 59-63
    CrossrefPubMedGoogle Scholar
  • 104 Stöckler S, Holzbach U, Hanefeld F , et al. Creatine deficiency in the brain: a new, treatable inborn error of metabolism. Pediatr Res 1994; 36 (3) 409-413
    CrossrefPubMedGoogle Scholar
  • 105 Glunde K, Bhujwalla ZM, Ronen SM. Choline metabolism in malignant transformation. Nat Rev Cancer 2011; 11 (12) 835-848
    PubMedGoogle Scholar
  • 106 Ross BD, Bluml S, Cowan R, Danielsen E, Farrow N, Gruetter R. In vivo magnetic resonance spectroscopy of human brain: the biophysical basis of dementia. Biophys Chem 1997; 68 (1–3) 161-172
    CrossrefPubMedGoogle Scholar
  • 107 Pérez-Ruiz A, Julià-Sapé M, Mercadal G, Olier I, Majós C, Arús C. The INTERPRET decision-support system version 3.0 for evaluation of magnetic resonance spectroscopy data from human brain tumours and other abnormal brain masses. BMC Bioinformatics 2010; 11: 581
    CrossrefPubMedGoogle Scholar
  • 108 Srinivasan R, Vigneron D, Sailasuta N, Hurd R, Nelson SJ. A comparative study of myo-inositol quantification using LCmodel at 1.5 T and 3.0 T with 3 D 1H proton spectroscopic imaging of the human brain. Magn Reson Imaging 2004; 22 (4) 523-528
    CrossrefPubMedGoogle Scholar
  • 109 Cigna Medical Coverage Policy no.0244. 2010. Available at: http://www.cigna.com/customer_care/healthcare_professional/coverage_positions/medical/mm_0244_coveragepositioncriteria_magnetic_resonance_spectroscopy.pdf . Accessed October 1, 2012
    PubMedGoogle Scholar
  • 110 Anthem Medical Policy RAD. 00022. 2012. Available at: http://www.anthem.com/medicalpolicies/policies/mp_pw_a053262.htm . Accessed October 1, 2012
    PubMedGoogle Scholar
  • 111 Blue Cross Blue Shield of Delaware Medical Policy 6.01.34. 2012. Available at: http://www.bcbsde.com/ProviderPolicies/public_site/6.01.34_Magnetic_Resonance_Spectroscopy.htm . Accessed October 1, 2012
    PubMedGoogle Scholar
  • 112 Blue Cross Blue Shield Blue Care Network Medical Policy Michigan 110111.MXD. 2011. Available at: http://www.bcbsm.com/mprApp/MedicalPolicyDocument?fileId=2036662 . Accessed October 1, 2012
    PubMedGoogle Scholar
  • 113 Excellus Policy Number 6.01.03. 2011. Available at: http://www.excellusbcbs.com/wps/wcm/connect/90e97c8044fba9ed9be4fbef58edd5a7/mp+mrs+tac+11.pdf?MOD=AJPERES . Accessed October 1, 2012
    PubMedGoogle Scholar
  • 114 Highmark West Virginia Medical Policy X-50. 2011. Available at: http://www.highmarkbcbswv.com/medpolicy/X-50-006.html . Accessed October 1, 2012
    PubMedGoogle Scholar
  • 115 Lifewise Medical Policy 6.01.514. 2012. Available at: http://www.lifewisewa.com/lwwa/groups/public/documents/medicalpolicy/cmi_041957.htm . Accessed October 1, 2012
    PubMedGoogle Scholar
  • 116 Medical Fee Schedule OWCP. 2010. Available at: http://www.dol.gov/owcp/regs/feeschedule/fee/fee10/PublicUseFileDirectory2010.htm . Accessed October 1, 2012
    PubMedGoogle Scholar
  • 117 Lin A, Clements V, Tran T, Ross B. Reimbursement for Magnetic Resonance Spectroscopy. In: Proceedings 17th Scientific Meeting, International Society for Magnetic Resonance in Medicine. Berkeley, CA: International Society for Magnetic Resonance in Medicine; 2009: 2509
    Google Scholar
  • 118 Fryback DG, Thornbury JR. The efficacy of diagnostic imaging. Med Decis Making 1991; 11 (2) 88-94
    CrossrefPubMedGoogle Scholar